Skip to main content

Table 3 Association of the CD8+, Granzyme B+, Foxp3+ or IL17+ TIL number and clinicopathological characteristics in NPC patients

From: Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways

Characteristics CD8 Positive Granzyme B Positive Foxp3 Positive IL17 Positive
  ≤52.50
(n = 53) 		> 52.50
(n = 53) 		P ≤32.45
(n = 53) 		> 32.45
(n = 53) 		P ≤74.00
(n = 53) 		>74.00
(n = 53) 		P ≤5.60
(n = 54) 		>5.60
(n = 52) 		P
Age, years             
≤49 27 27   21 34   24 31   27 28  
>49 26 25 0.846 32 19 0.011* 29 22 0.174 27 24 0.692
Gender             
Male 41 43   41 43   39 44   42 42  
Female 12 10 0.632 12 10 0.632 14 8 0.359 12 10 0.704
Tumor (T) stage             
T1+T2 28 29   22 35   21 36   26 31  
T3+T4 25 24 0.846 31 18 0.011* 32 17 0.003* 28 21 0.236
Lymphoid Nodal (N) status             
N0 13 5   9 9   10 8   9 9  
N1-3 40 48 0.038* 44 44 1.000 43 45 0.605 45 43 0.930
TNM Clinical stage             
I+II 21 17   16 22   14 24   15 23  
III+IVa+IVb 32 36 0.418 37 31 0.224 38 29 0.043* 39 29 0.077
LMP1             
- 25 31   30 26   28 28   31 25  
+ 27 20 0.195 22 25 0.494 23 24 0.914 21 26 0.280
  1. *P < 0.05, as determined by the Pearson chi2 test.
Back to article page